# MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)

> **NCT01028586** · PHASE3 · TERMINATED · sponsor: **Newron Pharmaceuticals SPA** · enrollment: 507 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** Safinamide, MAO-B inhibitor
- **DRUG:** Safinamide, MAO-B inhibitor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01028586
- **Lead sponsor:** Newron Pharmaceuticals SPA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2012-05
- **Final completion:** —
- **Target enrollment:** 507 (ACTUAL)
- **Why stopped:** Trial is terminated due to a company decision to return all rights for Safinamide back to Newron Pharmaceuticals
- **Last updated:** 2013-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01028586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01028586, "MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01028586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*